IMNN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies...

Stats
Today's Volume	16 252.00
Average Volume	219 524
Market Cap	13.16M
EPS	$0 ( 2024-05-13 )
Next earnings date	( $-0.550 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.650
ATR14	$0.0240 (1.70%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-13	Lindborg Stacy	Buy	112 500	Stock Option (Right to Buy)
2024-03-15	Church Jeffrey Wayne	Buy	25 000	Stock Option (Right to Buy)
2024-03-15	Anwer Khursheed	Buy	25 000	Stock Option (Right to Buy)
2024-03-15	Tardugno Michael H	Buy	12 500	Stock Option (Right to Buy)
2024-03-15	Fritz Frederick J.	Buy	3 500	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 100 transactions
Buy: 4 785 167 \| Sell: 160 000

Volume Correlation

Long: -0.04 (neutral)

Short: 0.16 (neutral)

Signal:(47.5) Neutral

Imunon, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Imunon, Inc. Correlation - Currency/Commodity

0.20
( neutral )

0.00
( neutral )

0.31
( neutral )

0.00
( neutral )

-0.38
( neutral )

Imunon, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-720 005 (0.00 %)
EPS:	$-2.16

FY	2023
Revenue:	$0
Gross Profit:	$-720 005 (0.00 %)
EPS:	$-2.16

FY	2022
Revenue:	$500 000
Gross Profit:	$-231 629 (-46.33 %)
EPS:	$-5.03

FY	2021
Revenue:	$500 000
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.83

Financial Reports:

No articles found.

Imunon, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Imunon, Inc.

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.